New Drug Delivery System Targets Diseases at a Genetic Level

News   Dec 06, 2017 | Original story from University of Connecticut

 
New Drug Delivery System Targets Diseases at a Genetic Level

Enzyme-triggered degradation of a drug loaded peptide-crosslinked nucleic acid nanocapsule. First a peptide is crosslinked at the nanoparticle surface (1), then an enzyme recognizes the peptide crosslinker (2), and finally the enzyme cleavage leads to the release of the drug and any intact DNA (3). Credit: (Artwork by Joseph Luciani/UConn)

 
 
 

RELATED ARTICLES

Neuromodulation of Behavior and Individuality Measured Over a Life-Time

News

Researchers illuminate the biology that guides behavior across different stages of life, and also suggest how variations in specific neuromodulators in the developing nervous system may lead to occasional variations.

READ MORE

Drug Transport Gene May Explain Why Ovarian Cancer Patients React Differently to Chemotherapy

News

A gene which produces a protein that transports drugs in and out of cells may explain why some women treated with chemo have serious side effects.

READ MORE

Tiny Kidneys: Building Better Models to Test Drugs

News

A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Analysis & Separations Cell Science Drug Discovery Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE